LWA Stock Overview
ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ECO Animal Health Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.18 |
| 52 Week High | UK£1.49 |
| 52 Week Low | UK£0.94 |
| Beta | 0.069 |
| 1 Month Change | 23.56% |
| 3 Month Change | -3.28% |
| 1 Year Change | -10.61% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -55.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| LWA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 11.3% | 1.9% | 1.2% |
| 1Y | -10.6% | -28.2% | 2.0% |
Return vs Industry: LWA exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: LWA underperformed the German Market which returned 2% over the past year.
Price Volatility
| LWA volatility | |
|---|---|
| LWA Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: LWA has not had significant price volatility in the past 3 months.
Volatility Over Time: LWA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | 234 | David Hallas | www.ecoanimalhealthgroupplc.com |
ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites, such as worms, ticks, mange, and lices in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle.
ECO Animal Health Group plc Fundamentals Summary
| LWA fundamental statistics | |
|---|---|
| Market cap | €85.08m |
| Earnings (TTM) | -€1.90m |
| Revenue (TTM) | €103.35m |
0.8x
P/S Ratio-44.9x
P/E RatioIs LWA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LWA income statement (TTM) | |
|---|---|
| Revenue | UK£88.46m |
| Cost of Revenue | UK£50.38m |
| Gross Profit | UK£38.08m |
| Other Expenses | UK£39.70m |
| Earnings | -UK£1.62m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.024 |
| Gross Margin | 43.05% |
| Net Profit Margin | -1.83% |
| Debt/Equity Ratio | 0% |
How did LWA perform over the long term?
See historical performance and comparison